LEVELS OF NON-HIGH-DENSITY LIPOPROTEIN CHOLESTEROL DO NOT NEGATIVELY IMPACT THE ABILITY OF THE PCSK9 INHIBITOR, EVOLOCUMAB, TO PROMOTE REGRESSION OF CORONARY ATHEROSCLEROSIS

Levels of non-HDL-C reflect the total circulating pool of atherogenic lipid factors and have been associated with ongoing plaque progression on statin treatment. It is unknown whether these levels modulate the degree of regression observed with addition of a proprotein convertase subtilisin kexin